Preclinical in vivo-models to investigate HIPEC; current methodologies and challenges

Roxan F. C. P. A. Helderman, Daan R. Löke, Pieter J. Tanis, Jurriaan B. Tuynman, Wim Ceelen, Ignace H. de Hingh, Kurt van der Speeten, Nicolaas A. P. Franken, Arlene L. Oei, H. Petra Kok, Johannes Crezee*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments.
Original languageEnglish
Article number3430
JournalCancers
Volume13
Issue number14
DOIs
Publication statusPublished - 2 Jul 2021

Cite this